p3xFLAG CMV14 / BRAF Citations (1)

Originally described in: Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.
Noeparast A, Teugels E, Giron P, Verschelden G, De Brakeleer S, Decoster L, De Greve J Oncotarget. 2016 Aug 26;8(36):60094-60108. doi: 10.18632/oncotarget.11635. eCollection 2017 Sep 1. PubMed Journal

---

Articles Citing p3xFLAG CMV14 / BRAF

Articles
Principles of CRISPR-Cas13 mismatch intolerance enable selective silencing of point-mutated oncogenic RNA with single-base precision. Shembrey C, Yang R, Casan J, Hu W, Chen H, Singh GJ, Sadras T, Prasad K, Shortt J, Johnstone RW, Trapani JA, Ekert PG, Fareh M. Sci Adv. 2024 Dec 20;10(51):eadl0731. doi: 10.1126/sciadv.adl0731. Epub 2024 Dec 18. PubMed

If you have published an article using this material, please email us at to have your article added to this page.